in all subjects, and the changes significantly correlated with an arbitrary score of the total administered dose of GCS (r 0.57, p < 0.05). These data suggest that neutrophil activation plays a minor role in asthma, and that treatment with GCS is not able to modify most functions of peripheral neutrophils in asthmatic subjects; chemotaxis seems to be related only to the severity of the asthma and it could reflect the improvement of the disease.
Introduction
Asthma has been defined as reversible airway obstruction, associated with nonspecific bronchial hyperresponsiveness, which is sustained by a chronic airway inflammation. Pathology of fatal asthma 2 and direct in vivo measurements of indices of airway inflammation by bronchoalveolar lavage (BAL) and bronchial biopsy 3'4 has confirmed the major role played by the recruitment of inflammatory cells in the airways of subjects with asthma of different severity.
While eosinophils are pivotal cells in asthma, the role of neutrophils in the pathophysiology of asthma is still uncertain. Neutrophil counts are increased in bronchial (BL) and bronchoalveolar lavage (BAL) of animals and humans after acute exposure to allergens, chemicals (like toluene diisocyanate, TDI) or oxidants (like ozone); [5] [6] [7] but in the stable phase, asthmatics show neutrophil counts in BAL or in bronchial biopsy that are not different from those found in normal 9 subjects.' Markers of activation of neutrophils have been inconsistently demonstrated in the (C) 1995 Rapid Science Publishers blood of asthmatic subjects. Peripheral neutrophils of asthmatic subjects seem to have higher releasability of mediators, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] higher superoxide anion generation 1 and higher migratory activity 11 than in normal subjects. However, the differences between asthmatic and normal subjects are mild; the observed abnormalities are not strictly related to the severity of asthma and they do not change significantly with the treatment of asthma. Thus, the significance of these abnormalities in the pathophysiology of the disease has not been demonstrated. Since An arbitrary score of the total dose of GCS administered during all periods of treatment (daily dose of 6-methyl-prednisolone or equivalent dose of deflazacort x number of days of treatment) was computed for each patient. Responders had a similar score to non-responders. This score was not significantly related to changes in the haematology or indices of neutrophil functions; there was only a significant relationship between this score and the decrease after treatment in chemokinesis from isolated peripheral neutrophils (r 0.57, p < 0.05).
There was no difference in the changes of indices of neutrophil activity between subjects who received regular beta.-agonists in addition to systemic GCS treatment and subjects who did not, nor between subjects who were previously treated with inhaled GCS and those treated with cromones.
Discussion
We showed that treatment with systemic GCS, at doses able to induce a significant improvement in pulmonary function in asthmatic subjects, was able to cause minimal effects on some indices of activity of peripheral blood neutrophils. Chemotaxis towards E. coli endotoxin was the only marker of neutrophil activity which significantly reduced after GCS in subjects who 29 the difference between blood and BAL neutrophils, although hypothetical, is not very probable.
As an additional finding, this study shows that most functions of peripheral neutrophils from asthmatic subjects during asthma exacerbations are not different from those measured in a small group of normal subjects, except for superoxide anion generation. Furthermore, chemotaxis toward E. coli endotoxin was significantly correlated with an index of asthma severity like FEV.
The partial disagreement between previous data [1] [2] [3] [4] [5] [6] and our observation regarding the increased capability of peripheral neutrophils to generate arachidonic acid metabolites and superoxide anion, could be explained by the small group of normal subjects in our study, by some methodological differences and by the different severity of the disease.
In conclusion, our study shows that neutrophil activation plays a minor role in asthma, and that treatment with systemic GCS is not able to modify most neutrophil functions in asthmatic subjects. Chemotaxis only seems to be related to the severity of asthma and it could reflect the improvement of the disease after GCS treatment.
However, further studies on airway neutrophils are needed.
